PCVX vs. SNY: Vaxcyte vs. Sanofi Stock Comparison

Company Profile

Vaxcyte (PCVX) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Sanofi (SNY) has more than two decades of public-market history since July 1, 2002, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Vaxcyte (PCVX) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Sanofi (SNY) reports 5.72%, ranking against industry peers normally.

Sanofi (SNY) at 8.20% retains a top-quartile share of revenue as profit, ahead of Vaxcyte (PCVX) at 0.00%, which keeps about the industry-typical share.

Sanofi (SNY) at 30.89% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Sanofi (SNY) reports revenue growth of 5.49%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Both Vaxcyte (PCVX) at 0.09 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Vaxcyte (PCVX) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Vaxcyte (PCVX) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Sanofi (SNY) trades at 23.40 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

A sales-based read is only available for Sanofi (SNY), whose P/S ratio of 2.21 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Vaxcyte (PCVX) at 3.83 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics